How does stiripentol affect GABA compared with fenfluramine?
Stiripentol is widely described as a modulator of inhibitory GABAergic signaling. In clinical and preclinical epilepsy literature, it’s commonly discussed as increasing GABA-mediated activity and enhancing inhibitory neurotransmission, which can help counter seizure activity.
Fenfluramine’s primary mechanism is different: it mainly acts through serotonergic pathways (and related downstream effects on neuronal excitability). While it can influence inhibitory tone in the brain, its direct “headline” target is serotonin rather than GABA.
What’s the main drug target for each—GABAergic modulation vs serotonin-driven effects?
Stiripentol: best characterized as acting on GABA-related processes, shifting the balance toward more inhibition through enhanced GABA function.
Fenfluramine: best characterized as acting on serotonin signaling (5-HT pathways), with any GABA-related changes viewed as secondary or downstream rather than its core mechanism.
Why might both drugs feel “inhibitory” even though their mechanisms differ?
Even if both can reduce seizures, they do it through different entry points into brain signaling networks. Stiripentol pushes more directly on the inhibitory GABA system. Fenfluramine starts with serotonergic modulation that can alter excitability and downstream inhibitory/excitatory balance, which may include effects that ultimately involve GABAergic tone—but not by directly targeting GABA as its primary mechanism.
Do they differ in how that could show up clinically?
Because they act on different neurotransmitter systems, their clinical profiles can differ even when both are used for epilepsy. Stiripentol is typically used as an add-on therapy in specific epilepsy syndromes, often alongside other anti-seizure medicines, consistent with its role as an inhibitory-pathway modulator. Fenfluramine is used for other specific epilepsy indications and is structured around serotonergic mechanism-based pharmacology.
What people usually mean when they say “GABA impact” for these two drugs
If someone says “stiripentol increases GABA,” they’re referring to its role in strengthening inhibitory GABAergic signaling. If someone says “fenfluramine impacts GABA,” they’re usually referring to indirect downstream network effects rather than fenfluramine being classified primarily as a GABAergic drug.
---
Sources were not provided with your prompt. If you share the references or the specific mechanism statements you’re using (e.g., from a paper, label, or guideline), I can rewrite the answer tightly around those exact claims with precise citations.